422
Views
10
CrossRef citations to date
0
Altmetric
Letters to the Editor

Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience

ORCID Icon, , , , , , , , , & show all
Pages 3255-3258 | Received 06 May 2020, Accepted 15 Jul 2020, Published online: 10 Aug 2020
 

Authors’ contributions

EA was responsible for the study design, collected the clinical data and wrote the report.

SP, MS, AB, MM and IA collected the clinical data and approved the final version of the manuscript.

FP, MA and FC was responsible for the analysis and interpretation data of amyloidosis.

AB, CN contributed to the critical review and finalized the report.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.